Cigna Corporation

Cigna Corporation (CI) (Q4FY23) – Unraveling customer growth, financial resilience, and shareholder rewards

Highlights of the report

The company recently boosted its quarterly dividend by an impressive 14%, reaching $1.40 per share, showcasing both financial resilience and a dedication to rewarding shareholders.

Cigna Corporation (CI) Equity Report Q4FY23

CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.


CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).


Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States.

While CI posted increasing revenue of $51.11bn in Q4FY23 compared to last year’s Q4FY22 of $45.73bn. On the surface, revenue increased by 12%. Operating income increased to $582mn in Q4FY23 from $1.67bn in Q4FY22. Net income increased massively to $1.02bn in Q4FY23 from $1.19bn in Q4FY22

Over the last 3 months Cigna Corporation stock has generated positive return of 31.74%, the price of stock has increased to $339.82 as on 7th March 2024 from $257.94 on 8th Dec 2023.



– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Metrics
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance


Stock Price Performance

Crispidea Coverage

Report details

Cigna Corporation (CI) (Q4FY23) – Unraveling customer growth, financial resilience, and shareholder rewards



Company Reports

Sector Reports